Jim Simons Legend Biotech Corp Transaction History

Renaissance Technologies LLC

$63.1 Billion
Q3 2024

A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Legend Biotech Corp stock. As of the latest transaction made, Renaissance Technologies LLC holds 18,100 shares of LEGN stock, worth $719,475. This represents 0.0% of its overall portfolio holdings.

Number of Shares

18,100

Holding current value

$719,475

% of portfolio

0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$43.55 - $59.88 $788,255 - $1.08 Million	18,100 New	18,100 $882,000
Q4 2023 Feb 13, 2024	BUY	$57.25 - $69.74 $1.25 Million - $1.52 Million	21,800 Added 21.76%	122,000 $7.34 Million
Q3 2023 Nov 14, 2023	BUY	$63.16 - $76.5 $5.44 Million - $6.59 Million	86,100 Added 610.64%	100,200 $6.73 Million
Q2 2023 Aug 11, 2023	SELL	$46.28 - $75.01 $1.26 Million - $2.04 Million	-27,200 Reduced 65.86%	14,100 $973,000
Q1 2023 May 12, 2023	BUY	$43.42 - $57.37 $451,568 - $596,648	10,400 Added 33.66%	41,300 $1.99 Million
Q4 2022 Feb 13, 2023	SELL	$38.8 - $55.46 $1.52 Million - $2.18 Million	-39,300 Reduced 55.98%	30,900 $1.54 Million
Q3 2022 Nov 14, 2022	BUY	$38.15 - $57.1 $2.68 Million - $4.01 Million	70,200 New	70,200 $2.86 Million
Q2 2022 Aug 12, 2022	SELL	$33.54 - $55.0 $6.07 Million - $9.96 Million	-181,100 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$31.02 - $48.18 $5.62 Million - $8.73 Million	181,100 New	181,100 $6.58 Million
Q3 2021 Nov 12, 2021	SELL	$35.31 - $50.56 $2.15 Million - $3.07 Million	-60,800 Closed	0 $0
Q2 2021 Aug 13, 2021	BUY	$25.8 - $41.09 $1.57 Million - $2.5 Million	60,800 New	60,800 $2.5 Million

Others Institutions Holding LEGN

# of Institutions

225

Shares Held

74.3M

Call Options Held

279K

Put Options Held

350K

View Full List

About Legend Biotech Corp

Ticker LEGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 167,403,008
Market Cap $6.65B
Description
Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multipl...

More about LEGN

Track Jim Simons's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.

Account